URL | https://www.fiercepharma.com/pharma/italian-plasma |
Source | Fierce Pharma |
Date Published | 09/29/2025 |
Author Name | Kevin Dunleavy |
Company/Division name | Kedrion Biopharma |
Parent company | Kedrion Biopharma |
Type of work | Manufacturing |
Reshoring category: | Foreign Direct Investment |
Year reshoring announced: | 2025 |
Capital investment ($): | 260 |
City reshored to: | Melville |
State(s) reshored to: | NY |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | pharma |
What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |